非小细胞肺癌患者EGFR基因突变与血清肿瘤标志物之间关系探讨

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the relationship between EGFR gene mutation and serum tumor markers in non-small cell lung cancer (NSCLC) patients and investigate the tumor markers that can predict the EGFR gene mutation. Methods: Retrospectively analyze of 188 NSCLC patients’ clinical characteristic in our hospital, who were detected EGFR gene mutation from October 2010 to August 2013. All the patients tested the serum tumor markers before treatment. Statistical methods were used to analyze the relationship between EGFR gene mutation and basic clinical characteristics and serum tumor markers. Results: 188 NSCLC patients were enrolled, and mutation rate was 44.7 percent. EGFR gene mutation was mainly occurred in women, non-smoking and adenocarcinoma patients (P<0.05). When the serum CEA>20 μg/L, or the serum SCCAg≤1.5 μg/L, EGFR mutation rate was significantly increased. Most importantly, EGFR mutation rate was highest when SCCAg≤1.5 μg/L and CEA>20 μg/L group, and the difference was statistically significant (P<0.05). While there was no correlation between CYFRA21-1, NSE, CA125, CA199 and EGFR gene mutation (P>0.05). Conclusion: For the patients whose EGFR gene mutation can not be tested, we can chose those whose serum SCCAg≤1.5 μg/L and CEA>20 μg/L, and according to the patients’ clinical characteristic, with EGFR-TKIs treatment.

Key words： carcinoma, non-small cell lung receptor, epidermal growth factor tyrosine gene mutation tumor markers

Received: 17 March 2014

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PU Guimei1
	3
	YE Junru1
	LU Yao1
	CHEN Bicheng2
	OUYANG Jinsheng1
	LI Yuping1

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2014/V44/I9/667

[1]Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J].CA Cancer J Clin, 2013, 63(1): 11-30.
[2]Hirata H, Nakamura K, Kunitake N, et al. Association be-tween EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma[J]. Anticancer Res, 2013, 33(4): 1649-1655.
[3]Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cis-platin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(2): 121-128.
[4]Pallis AG, Syrigos KN. Epidermal growth factor receptor ty-rosine kinase inhibitors in the treatment of NSCLC[J]. Lung Cancer, 2013, 80(2): 120-130.
[5]钱小英, 叶环, 施肖红, 等. 肺癌患者外周血癌胚抗原、糖类抗原水平与肺癌分期、转移及预后的关系[J]. 温州医学院学报, 2008, 38(5): 264-266.
[6]Shoji F, Yoshino I, Yano T, et al. Serum carcinoembryon-ic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas[J].Cancer, 2007, 110(12): 2793-2798.
[7]Okamoto T, Nakamura T, Ikeda J, et al. Serum carcino-embryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer[J]. Eur J Cancer, 2005, 41(9): 1286-1290.
[8]Zornosa C, Vandergrift JL, Kalemkerian GP, et al. First-Line Systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions[J]. J Natl Compr Canc Netw, 2012, 10(7): 847-856.
[9]Shigematsu H, Lin L, Takahashi T, et al. Clinical and biolog-ical features associated with epidermal growth factor recep-tor gene mutations in lung cancers[J]. J Natl Cancer Inst, 2005, 97(5): 339-346.
[10]徐琳, 郑明峰, 张稷, 等. EGFR突变基因检测与肿瘤指标相关性研究[J]. 医学研究杂志, 2011, 40(8): 79-81.
[11]Pan JB, Hou YH, Zhang GJ. Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients[J]. Asian Pac J Cancer Prev, 2013, 14(2): 695-700.
[12]Petra S, Rudof H, Stefan H, et a1. National academy of clin-ical biochemistry guidelines and recommendations for use of tumor markers in lung cancer. (Section 3P)[EB/OL].http://www.aacc.org/SiteCollectionDocuments/NACB/LMPG/tumor/chp3p_lung.pdf.
[13]Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagno-sis of advanced lung cancer based on small biopsies and cytology:a paradigm shift[J]. J Thorac Oncol, 2010, 5(4): 411-414.
[14]Tanaka K, Hata A, Kaji R, et al. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-ty-rosine kinase inhibitor in non-small-cell lung cancer harbor-ing EGFR mutation[J]. J Thorac Oncol, 2013, 8(7): 892-898.